ArticleJournal of clinical microbiology2008
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Using Phenotypic, Biochemical, and Molecular Methods to IdentifyEpidemiologia (Basel, Switzerland) · 2026Article
- Identification of Clinically Relevant Yeasts from Avian Isolates Using API ID32C, MALDI-TOF MS, and ITS Sequencing: Potential Relevance from a One Health Perspective.Veterinary sciences · 2026Article
- Citywide metagenomic surveillance of food centres reveals local microbial signatures and antibiotic resistance gene enrichment.npj antimicrobials and resistance · 2025Article
- Review
- Phenotypic and genotypic characterization of Candida parapsilosis complex isolates from a Lebanese hospital.Scientific reports · 2025Article
- Fluconazole resistant pathogenic yeasts isolated from plastic debris on recreational public beaches in West and East Africa.Biologia · 2025Article
- Threats from theMicrobiology and molecular biology reviews : MMBR · 2024Review
- Short Tandem Repeat Genotyping of Medically Important Fungi: A Comprehensive Review of a Powerful Tool with Extensive Future Potential.Mycopathologia · 2024Review
- Phenotypic and Genotypic Characterization of Candida parapsilosis complex isolates from a Lebanese Hospital.Research square · 2024Article
- Disseminated Lodderomyces elongisporus and Pantoea dispersa: A Rare Dual Infection in an Immunocompromised Patient.Cureus · 2024Article
- Saprochaete/Magnusiomyces: identification, virulence factors, and antifungal susceptibility of a challenging rare yeast.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The Emerging PathogenInfection and drug resistance · 2024Review
- A genome-informed higher rank classification of the biotechnologically important fungal subphylumStudies in mycology · 2023Article
- Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.The Lancet. Microbe · 2023Review
- Molecular Investigation of the Fatal BloodstreamInternational journal of molecular sciences · 2023Article
- FatalJournal of fungi (Basel, Switzerland) · 2022Article
- Global Prevalence of Antifungal-ResistantTropical medicine and infectious disease · 2022Review
- Identification of a novel Candida metapsilosis isolate reveals multiple hybridization events.G3 (Bethesda, Md.) · 2022Article
- Genetic Manipulation as a Tool to UnravelJournal of fungi (Basel, Switzerland) · 2021Review
- Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis.Mycopathologia · 2021Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida orthopsilosis and Candida metapsilosis are recently described species, having previously been grouped with the more prevalent species Candida parapsilosis. Current literature contains very little data pertaining to the distributions and antifungal susceptibilities of these Candida species. We determined the species and antifungal susceptibilities of 1,929 invasive clinical isolates from the ARTEMIS antifungal surveillance program collected between 2001 and 2006 and identified as C. parapsilosis using Vitek and conventional methods. Of the 1,929 isolates of presumed C. parapsilosis tested, 117 (6.1%) were identified as C. orthopsilosis and 34 (1.8%) as C. metapsilosis. The percentage of presumed C. parapsilosis isolates found to be C. orthopsilosis varied greatly by region, with the highest percentage (10.9%) from South America and the lowest (0.7%) from Africa. The MIC distributions of the C. orthopsilosis and C. metapsilosis isolates were statistically significantly lower than those of C. parapsilosis for all drugs except fluconazole, for which they were significantly higher (P < 0.001 for all). No C. orthopsilosis or C. metapsilosis isolates were fluconazole resistant, and all were susceptible to caspofungin, anidulafungin, and micafungin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.